Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)

The efficacy of irinotecan plus continuous trastuzumab beyond progression in patients with gastric cancer previously treated with trastuzumab plus standard first-line chemotherapy has not been reported. Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer wh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2022-05, Vol.27 (5), p.340-e374
Hauptverfasser:	Kawamoto, Yasuyuki, Yuki, Satoshi, Meguro, Takashi, Hatanaka, Kazuteru, Uebayashi, Minoru, Nakamura, Michio, Okuda, Hiroyuki, Iwanaga, Ichiro, Kato, Takashi, Nakano, Shintaro, Sato, Atsushi, Harada, Kazuaki, Oba, Koji, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antimitotic agents Antineoplastic agents Cancer Cancer patients Care and treatment Chemotherapy Chemotherapy, Combination Clinical Trial Results Complications and side effects Development and progression Diagnosis Dosage and administration Drug therapy Epidermal growth factor Oncology, Experimental Stomach cancer Testing Trifluridine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!